Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)

NCT ID: NCT05172193

Last Updated: 2022-09-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 600 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-31
• Study Completion Date: 2023-09-30

Brief Summary

The 2019 Coronavirus disease outbreak (COVID-19) was first reported at the end of 2019 in Wuhan China as a severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection. In less than a year, SARS-CoV-2 infection has become a pandemic and spread to almost all countries in the world, including Indonesia. World Health Organization data states that there are 4,240,479 confirmed cases of SARS-CoV-2 in Indonesia until 25 October 2021 with a death rate of 143,235 (WHO, 2021a).

The Indonesian National Agency of Drug and Food Control (NA-DFC) has issued an Emergency Use Authorization for several SARS-COV-2 Vaccines, including the SARS-CoV-2 vaccine (Vero cell) inactivated produced by Sinopharm (BPOM, 2021). Clinical data that the actual immune responses decrease after several months are continuously being reported (Marmot et al., 2021), and the decrease of vaccine efficacy due to the appearance of variants is also known (Abu-Raddad et al., 2021; Lopez Bernal et al., 2021). These potential risks suggest the need for a booster dose or periodic booster doses of the SARS-COV-2 Vaccine. In fact, there is a study result given several months after vaccination, which leads to the generation of a higher immune responses (Pan H et al., 2021). Booster dose of SARS-COV-2 Vaccine will either induce a high level of antibody responses against original strain, or enhance the broadly formed T cell immunity regardless of mutant strain to improve individual protection.

Conditions

COVID-19

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated

One booster dose 0.5 mL IM injection of SARS-COV-2 Vaccine (Vero Cell) Inactivated

Group Type: EXPERIMENTAL

SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated

Intervention Type: BIOLOGICAL

SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.

Interventions

SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated

SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Adult males or females aged 18 years and above at the time of consent.

2. Participants who provide a voluntarily consent to participate in the study and sign the consent form.

3. Participants who have previously received homologous 2-dose of SARS-COV-2 Vaccine (either Vero Cell inactivated-Sinopharm SARS-COV-2 Vaccine, CoronaVac SARS-COV-2 Vaccine, or Cominarty/Pfizer mRNA COVID-19 Vaccine) authorized for emergency use, between 6 to 12 months post second prime vaccine dose prior to Day 1.

4. Participants who have negative results for swab SARS-COV-2 rapid antigen test.

Exclusion Criteria

1. Participants who are unable to follow clinical and follow-up procedures.

2. Participants with acute fever with temperature above 38℃, coughing, breathing difficulty, chills, muscle ache, headache, sore throat, loss of smell, or loss of taste within 72 hours prior to the dosing.

3. Participants with a history of PCR-confirmed SARS-CoV-2 infection in the last 90 days prior to dosing.

4. Female who are pregnant or breastfeeding.

5. Participants with a history of hypersensitivity or allergic reactions including anaphylaxis.

6. Participants with immune dysfunction, including immunodeficiency disorder, or family history of such conditions, except HIV-positive participants in stable/well-controlled condition.

7. Participants who received chronic administration (defined as more than 14 continuous days) of immunosuppressant medication such as immunomodulator, immune-modifying drug, immunoglobulin, immunotherapy, chemotherapy, systemic corticosteroid, etc. except topical steroids or short-term oral steroids (course lasting ≤ 14 days), or blood-derived products in the last 90 days prior to dosing.

1. Hospitalization for the condition, including day surgical interventions

2. New significant organ function deterioration

3. Needing addition of new treatments or major dose adjustments of current treatments (mild or moderate well-controlled comorbidities are allowed)

9. Participants with hemophilia or people using anticoagulants who are at a risk of serious bleeding from IM injection.

10. Participants with a current dependent on antipsychotic drugs and narcotic analgesics, or suspected of alcohol or drug dependency.

11. Participants who have received or plans to receive other vaccination(s) within 28 days prior to or during study duration (except for influenza vaccine which is not allowed within 14 days before, or 4 weeks after final dose of IP).

12. Participants who have received or have plans to receive other investigational drug(s) while participating in another clinical study or bioequivalence study within 28 days prior to vaccination. -

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

PT. Kimia Farma (Persero) Tbk

INDUSTRY

Sponsor Role: lead

Responsible Party

Prenali Dwisthi Sattwika

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Universitas Udayana Hospital

Badung, Bali, Indonesia

Site Status: COMPLETED

Bali Mandara Hospital

Denpasar, Bali, Indonesia

Site Status: COMPLETED

Kimia Farma Soetomo Clinic and Laboratorium

Semarang, Central Java, Indonesia

Site Status: RECRUITING

JIH Hospital

Sleman, D.I. Yogyakarta, Indonesia

Site Status: COMPLETED

Kimia Farma Adisucipto Clinic and Laboratorium

Yogyakarta, D.I. Yogyakarta, Indonesia

Site Status: COMPLETED

Kimia Farma Diponegoro Clinic and Laboratorium

Bandung, West Java, Indonesia

Site Status: RECRUITING

Kimia Farma Radio Dalam Clinic and Laboratorium

Jakarta, , Indonesia

Site Status: RECRUITING

Countries

Indonesia

Central Contacts

Prenali Dwisthi Sattwika

Role: CONTACT

boost.vctrial@gmail.com

+62 274-560-455

Jarir At Thobari

Role: CONTACT

pusatcebu.fkkmk@ugm.ac.id

Facility Contacts

Research team

Role: primary

Research team

Role: primary

Research team

Role: primary

Other Identifiers

BOOST-VC-0221

Identifier Type: -

Identifier Source: org_study_id